Patents Assigned to Merck
  • Somatostatin agonists
    Patent number: 6387932
    Abstract: This invention relates to non-peptide somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retenosis. Many of the compounds are orally active.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Changyou Zhou, Alexander Pasternak, Gregori Morriello, Liangqin Guo, Yanping Pan, Lihu Yang, Arthur Patchett
  • DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
    Patent number: 6387695
    Abstract: The present invention relates to nucleic acid formulations of pharmaceutical products which comprise citrate and/or triethanolamine in concentrations which enhance stability of the nucleic acid. These formulations are suited for situations where prolonged storage occurs during the distribution and/or storage period prior to use.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Evans, David B. Volkin, Mark W. Bruner, Zheng Xu
  • Spirotricyclic substituted azacycloalkane derivatives and uses thereof
    Patent number: 6387893
    Abstract: Spirotricyclic azacycloalkyl compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds is also described. One application of these compounds, which are alpha 1a adrenergic receptor antagonists, is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ben E. Evans, Jacob M. Hoffman, Kevin F. Gilbert, Kenneth E. Rittle
  • Pesticidal formulation
    Patent number: 6387388
    Abstract: The present invention is directed to a pesticidal composition of a water-soluble pesticide and processes for its manufacture. More specifically, the invention relates to a soluble granule (SG) pesticidal formulation comprising a water-soluble pesticide and a water-soluble filler. The present invention provides a pesticidal formulation with efficacy equal to the corresponding liquid formulation, yet with improved handler safety, such as lower eye irritation.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: John Misselbrook, Robert F. Peterson, Jr.
  • Polymer beads
    Publication number: 20020055555
    Abstract: The invention relates to polymer beads comprising an anisotropic polymer material with helically twisted structure, to their use in reflective films, spraying or printing inks or as pigments, for optical or electrooptical, decorative or security applications, to a reflective film comprising one or more polymer beads in a transmissive binder, and to a security marking or security device comprising one or more polymer beads or comprising a reflective film.
    Type: Application
    Filed: September 18, 2001
    Publication date: May 9, 2002
    Applicant: MERCK PATENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Mathias Kuntz, David Coates, Simon Greenfield, John Patrick
  • Process for preparing electrically conductive pigments
    Publication number: 20020053661
    Abstract: The invention relates to a process for preparing electrically conductive pigments based on F−- and/or PO43−-doped tin mixed oxides applied as an electrically conductive layer to a substrate, in which, first of all, SnO2-coated substrates are prepared by precipitation and subsequent calcining and then, in further process steps, this SnO2 layer is converted into a tin mixed oxide layer doped with F− and/or PO43−. The invention further relates to electrically conductive pigments prepared by the process of the invention, to the use of these pigments for pigmenting lacquers, printing inks, plastics systems or coatings, and to lacquers, printing inks, plastics systems or coatings pigmented with an electrically conductive pigment prepared by the process of the invention.
    Type: Application
    Filed: October 19, 2001
    Publication date: May 9, 2002
    Applicant: MERCK PATENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: Ralf Glausch
  • Dry mix formulation for bisphosphonic acids
    Publication number: 20020054906
    Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
    Type: Application
    Filed: October 19, 2001
    Publication date: May 9, 2002
    Applicant: MERCK & Co., Inc.
    Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
  • UV-B filter
    Publication number: 20020055532
    Abstract: Disclosed is a 2-phenyl-benzimidazolesulfonic acid according to the formula 1
    Type: Application
    Filed: November 21, 2001
    Publication date: May 9, 2002
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Ulrich Heywang, Michael Schwarz, Frank Pflucker
  • Anticoccidial compounds
    Patent number: 6384052
    Abstract: Trisubstituted pyrroles are useful in the control of coccidiosis in poultry.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Bitfu, Danqing D. Feng
  • Process for the preparation of mineralized collagen fibrils and their uses as bone substitute material
    Patent number: 6384196
    Abstract: The invention relates to a process for the preparation of mineralized collagen fibrils, where the fibril formation and mineralization take place in one process step, and to the use thereof as bone substitute material. The collagen is recombinant collagen.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: May 7, 2002
    Assignee: Merck Patent Gesellschaft
    Inventors: Karl Weis, Wolfgang Pompe, Jens Bradt
  • Azlactone-derivatized polyamides
    Patent number: 6383584
    Abstract: The present invention relates to an azlactone-derivatized polyamide shaped article made by reacting at least one polyamide with a solution comprising an aza-bicyclo compound and a vinylazlactone derivative of the formula I wherein R1, R2, R3, R4, and R5 are defined herein.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 7, 2002
    Assignee: Merck Patent Geselleschaft mit beschrankter
    Inventors: Egbert Müller, Anja Seiler
  • Method for producing monohalogenated 2-oxo-1,3-dioxolanes
    Patent number: 6384239
    Abstract: The invention relates to a process for the preparation of monohalogenated 2-oxo-1,3-dioxolanes of the general formula C3H3XO3  (I) in which X is Cl or Br, characterized in that the monohalogenation is carried out starting from ethylene carbonate with sulfuryl dihalides under UV irradiation and in the absence of solvents.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Bernhard Seifert, Sylvia Becker
  • Method of treating migraines and pharmaceutical compositions
    Patent number: 6384034
    Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Kremena Simitchieva, Scott A. Reines, Errol McKinney, Eric J. Sandquiest, Deepak K. Khannna, Richard Hargreaves
  • Process for the preparation of mineralized collagen fibrils and their use as bone substitute material
    Patent number: 6384197
    Abstract: The invention relates to a process for the preparation of mineralized collagen fibrils, where the fibril formation and mineralization take place in one process step, and to the use thereof as bone substitute material. The collagen is natural collagen.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: May 7, 2002
    Assignee: Merck Patent Gesellschaft
    Inventors: Karl Weis, Wolfgang Pompe, Jens Bradt
  • Process for preparing cis- aminochromanols
    Patent number: 6384244
    Abstract: cis-aminochromanols are obtained in high yield and with high selectivity over their trans counterparts by hydrogenating the corresponding oximes in the presence of a catalyst and an acid selected from HBr, HCl, and organic sulfonic acid. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian Davies, Karl Hansen, Paul N. Devine, Louis Matty, Jr., Yuan Cheng, Philippe M. Rabbat
  • Polynucleotide tuberculosis vaccine
    Patent number: 6384018
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a Th1 type of helper T-cell response (i.e., high IL-2 and IFN-&ggr;). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M.bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer
  • Process for the production of human cartilage implants by means of chondrocytes cultivated in vitro
    Publication number: 20020052044
    Abstract: The invention describes a process for the production of a human cartilage implant from chondrocytes cultured in vitro, which come as close as possible to the original with respect to their biochemical composition and biomechanical properties. Up to 20% by vol. of human serum are used as medium addition in the process. The chondrocytes can be kept in monolayer culture until the 12th passage in order firstly to be re-differentiated, incubated under a reduced oxygen partial pressure, and subsequently stimulated to form a three-dimensional cartilage tissue due to aggregation under an oxygen partial pressure of 21%.
    Type: Application
    Filed: August 29, 2001
    Publication date: May 2, 2002
    Applicant: Merck KGAA; Darmstadt, Germany
    Inventors: Brigitte Jeschke, Jorg Meyer, Peter Adamietz, Norbert Meenen, Christiane Gopfert
  • Lactonization process
    Patent number: 6380401
    Abstract: Crystalline 3-hydroxylactone-containing products can be prepared in high yield and purity in a one-pot process by treating the corresponding 3,5-dihydroxy acid with a strong mineral acid in a cold, aprotic, water-miscible solvent to effect lactonization, followed by addition of excess acid to effect crystallization of the lactonized product from the reaction mixture.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: James McManus, Nicholas Anousis, John Genus, Christopher Hancock
  • Angiogenesis inhibitors
    Patent number: 6380203
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino
  • Pharmaceutical kit
    Patent number: D457246
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Sidney Mazel, James M. Mundt